Cantor Fitzgerald Reiterates eFFECTOR Therapeutics (EFTR) at Overweight, $50 PT, "Company's Pipeline Remains Underappreciated", Expect Advancements to Move Stock Higher
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50.00 price target on eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
